Valuation: Medios AG

Market Cap 251M 280M 235M 213M 399M 26.61B 402M 2.82B 1.1B 13.81B 1.05B 1.03B 44.42B P/E 2026 *
12.1x
P/E 2027 * 8.55x
Enterprise Value 347M 386M 324M 294M 551M 36.76B 555M 3.89B 1.52B 19.08B 1.45B 1.42B 61.35B EV / Sales 2026 *
0.16x
EV / Sales 2027 * 0.14x
Free-Float
92.4%
Yield 2026 *
-
Yield 2027 * -
3 years 13.64
Extreme 13.64
13.64
5 years 13.64
Extreme 13.64
50
10 years 13.64
Extreme 13.64
50
Manager TitleAgeSince
Chief Executive Officer 58 2026-01-31
Director of Finance/CFO 54 2026-04-14
Investor Relations Contact - -
Director TitleAgeSince
Chairman 53 2014-11-06
Director/Board Member 65 2016-09-13
Director/Board Member 57 2021-06-09
Change 5-day change 1-year change 3-year change Capi.($)
-72.72%-.--% - - 283M
+3.62%+1.68%+48.80%+96.02% 1,040B
+2.13%-1.76%+33.04%+61.18% 599B
+3.32%+4.47%+23.72%+92.54% 485B
+3.80%+3.21%+73.99%+41.51% 350B
+3.09%+6.03%+27.85%+45.42% 345B
+2.82%+4.68%+17.38%+40.15% 272B
+3.40%+2.86%-3.33%+12.08% 244B
+3.21%+3.15%+45.01%+48.53% 223B
+3.80%+4.56%+29.59%+93.86% 183B
Average -4.78%+2.38%+32.89%+59.03% 415.87B
Weighted average by Cap. +2.91%+2.31%+36.59%+67.74%

Financials

2026 *2027 *
Net sales 2.17B 2.41B 2.02B 1.83B 3.44B 229B 3.46B 24.28B 9.48B 119B 9.05B 8.85B 383B 2.25B 2.5B 2.1B 1.9B 3.57B 238B 3.59B 25.16B 9.82B 123B 9.38B 9.18B 397B
Net income 20.93M 23.28M 19.53M 17.7M 33.23M 2.21B 33.44M 234M 91.51M 1.15B 87.39M 85.49M 3.7B 29.51M 32.82M 27.54M 24.96M 46.85M 3.12B 47.15M 330M 129M 1.62B 123M 121M 5.21B
Net Debt 95.84M 107M 89.43M 81.06M 152M 10.14B 153M 1.07B 419M 5.26B 400M 392M 16.93B 56.45M 62.79M 52.68M 47.75M 89.65M 5.98B 90.2M 632M 247M 3.1B 236M 231M 9.97B
Projected Income Statement - Annual - Medios AG
Logo Medios AG
Medios AG, formerly Crevalis Capital AG, is a Germany-based company offering solutions in pharma industry. The Company covers relevant aspects of supply chain like from pharmaceutical supply and manufacture of patient-specific therapies, including blistering and others. It operates in two segments Pharmaceutical supply which focuses on pharmaceutical wholesale with finished specialty pharma (high-priced drugs for rare and chronic diseases) medications including oncology, neurology, autoimmunology, ophthalmology, infectiology, hemophilia along with offering finished medicinal products; Patient-specific therapies focusing on pharmaceutical manufacturing of patient-specific preparations such as Cytostatic infusions, Antibody therapies, Virostatic and antibiotic medications, Parenteral nutrition solutions, Investigational medicinal products are among others. Its products and services include Patient health & protection and procedures & processes for patient care and digitalization of data.
Employees
989
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Medios AG
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
10.32EUR
Average target price
20.25EUR
Spread / Average Target
+96.22%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Medios AG